Brief Introduction

Founded in 2008, Beijing Kawin Technology Share-Holding Co., Ltd. ("Kawin"; stock code 688687) is a biopharmaceutical company focused on viral diseases, and committed to offering treatment solutions based on our biotech platforms.

Kawin is located in the Beijing Economy-Technology Development Area (BDA), a national development zone in Beijing. Throughout our corporate development before IPO, Kawin established strategic partnerships with Legend Capital, Haitong Capital, Cybernaut, Lilly Asia Ventures (LAV), and meanwhile won several domestic honors such as Zhongguancun Top 100 High-growth Enterprise, and Beijing G20 enterprises (G20 projects). On February 8, 2021, Kawin was listed on Shanghai Stock Exchange STAR Market.

With R&D innovation as the core driver, our drug pipeline is set up mainly across innovative drugs. Our international R&D team strives their excellence in drug discover, CMC, quality control, formulations, pharmacology and clinical development. Kawin is technically specialized in the development of biological drugs from the beginning to the end by our own R&D force.

Kawin owns 7 GMP production lines for the production of biological and chemical products. The biological product lines include Small Volume Parenteral Solutions, Lyophilized Powder for Injection, and Effervescent Tablets. The chemical product lines include Small Volume Parenteral Solutions, Lyophilized Powder for Injection, Tablets, and Capsules. Among them, the chemical product lines of terminally sterilized injection received international GMP certification (PIC/S standard).

Kawin now has variety of commercialized products, such as Recombinant Human Interferon α2b Injection (凯因益生), Compound Glycyrrhizin Capsules (凯因甘乐), and Recombinant Human Interferon α2b Vaginal Effervescent Tablets (金舒喜), whose market shares rank among the top within the industry. In addition, as the part of "Kawin Scheme"-- the 1st native full oral and pan-genotype scheme to achieve high cure rate of Hepatitis C, our innovative drug Coblopasvir Hydrochloride Capsules (凯力唯) in combination with our Sofosbuvir Tablets (赛波唯) has been included in the China's National Reimbursement Drug List (NRDL). The launch of Kawin Scheme broke up the monopoly of imported HCV pan-genotype DAAs drugs and created more treatment option as well as benefits for HCV patients.

Oriented by clinical treatment needs, Kawin strives to become a pioneer in the antiviral area and dedicates into healthcare industry by developing innovative drugs and offering deliverable-based treatment solutions.

Company Overview

Full name Beijing Kawin Technology Share-Holding Co., Ltd.
Abbreviations Kawin
Code 688687
Founded 2008-08-20
Listing 2021-02-08
Domicile Beijing
STAR Theme Biomedicine
CSRC Sector Manufacturing
Has weighted voting rights structure? No



  2020 2019 2018
Earnings Per Share 0.59 0.44 0.37
R&D expenditure as a % of operating revenue 6.55% 4.29% 7.54%
Operating Revenue 862.05 824.92 705.86
Net Income 70.99 50.30 41.40

Income Statement (Unit: RMB mn)

  2020 2019 2018
Operating Revenue 862.05 824.92 705.86
Operating Costs 111.52 103.74 97.43
Operating Income 88.75 67.35 49.21
Pretax Income 87.81 67.16 49.18
Income Tax 16.82 16.86 7.79
Net Income 70.99 50.30 41.40

Balance Sheet(Unit: RMB mn)

  2020 2019 2018
Current Assets-Total 792.72 712.94 491.84
Non-current Assets-Total 379.48 339.57 322.72
Total Assets 1,172.20 1,052.52 814.56
Current Liabilities-Total 249.85 234.13 130.70
Non-current Liabilities-Total 68.72 46.54 28.99
Total Liabilities 318.56 280.67 159.69
Stockholder's Equity
Share Capital 667.42 667.42 596.54
Retained Profits 180.30 104.73 58.88
Minority Interests 5.92 -0.31 -0.54
Total Owners' Equity 853.63 771.85 654.87

Cash Flow Statement (Unit: RMB mn)

  2020 2019 2018
Net Cash Flows-Operating 131.42 102.94 60.31
Net Cash Flows-Investing -78.51 -47.53 -50.40
Net Cash Flows-Financing 8.48 47.21 0

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
北京松安投资管理有限公司 38.40 30.15%
天津君睿祺股权投资合伙企业(有限合伙) 14.32 11.24%
海通开元投资有限公司 7.89 6.20%
尚融宝盈(宁波)投资中心(有限合伙) 6.20 4.87%
宁波赛伯乐甬科股权投资合伙企业(有限合伙) 5.85 4.59%
北京卓尚湾企业管理中心(有限合伙) 5.04 3.96%
LAV Fortune(Hong Kong) Co., Ltd. 5.00 3.93%
高林厚健(上海)创业投资合伙企业(有限合伙) 4.00 3.14%
深圳前海方维股权投资合伙企业(有限合伙) 3.69 2.90%
苏州工业园区新建元二期生物创业投资企业(有限合伙) 3.50 2.75%
As of 2020-12-31

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.